—
C+
C+ The full Closelooknet — membership. Open the C+ overview

Roche Holding AG (ROP.SW) — chart, structure and Closelooknet read

The Closelooknet read

Roche Holding AG is a Swiss healthcare group split between pharmaceuticals and diagnostics, headquartered in Basel. Its medicines cover areas such as oncology, immunology, neurology, ophthalmology and infectious disease, while its diagnostics arm supplies tests and instruments used to detect conditions including cancer, diabetes and hepatitis.

Detail below: the desk's view, the earnings record, peers and the company snapshot; daily prices on the price-history tab. Agents can buy the score depth per call over HTTP 402 — see the catalogue. Research diary readings, not advice.

Pick a ticker to load its detail page.

Signals for this name

Every Closelooknet reading that exists for ROP.SW, from the same nightly bakes the boards use. Research diary readings, not advice.

Versus its index AI Users — the name, its sleeve and the index over day, week and month

Versus its index

The name against its Closelooknet index and its own sleeve — equal-weight, nightly closes.

AI Users · as of 2026-11-10

DayWeekMonth3 months
ROP.SW+0.2%+2.8%+11.6%+10.9%
Research, Design & Development−0.2%−2.8%+8.0%—
AI Users−0.1%+1.1%+5.5%—

Against the index: 1.7 pts ahead on the week, 6.1 pts ahead on the month; against its Research, Design & Development sleeve 3.6 pts ahead on the month.

Returns from the index workers’ nightly closes; equal-weight sleeves. A relative reading from the research diary, not advice.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 48/100 · S&P 500 fund at 51, above its 200-day averageEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-11-10
  • Factor regime Defensive rotation — low-vol leading, regime-change watchMomentum against low volatility (SPMO / SPLV): below its 50-day trend, 67th percentile of the window, -18.1% over 20 sessions. Factor regime → 2026-11-10
  • Sector × region Health care in Europe: +2.4% week · +14.5% month · +11.7% quarter · +16.3% yearThe Sector Engine cell this name lives in, from EXV4.XETRA; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-11-10
  • Sovereign pressure Index -1.67 · down 1.71 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-11-09
Who it is priced against AI Users · Research, Design & Development · 3 names with week and year-to-date

Peer group

AI Users · Research, Design & Development

Compared against ROP.SW on the nightly bakes; the Peers tab ranks the cohort on the Closelooknet scores where it exists.

Company snapshot — Roche Holding AG

ROP.SW in five paragraphs: what it makes and sells, where it sits in the Closelooknet stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Roche Holding AG is a Swiss healthcare group split between pharmaceuticals and diagnostics, headquartered in Basel. Its medicines cover areas such as oncology, immunology, neurology, ophthalmology and infectious disease, while its diagnostics arm supplies tests and instruments used to detect conditions including cancer, diabetes and hepatitis. The company was founded in 1896 and sells across North America, Europe, Latin America, Asia, Africa and Oceania.
Where it sits in the stack
Roche sits in the AI Users index (our index of companies deploying AI at scale to strengthen their existing businesses), in the Research, Design & Development section. It disclosed in February 2025 that AI-assisted antibody lead optimisation designed and tested more than 1,800 variants, producing binding improvements of three to 100 times, with scientists assessing the results rather than the system deciding on its own. It also disclosed in July 2024 a diagnostics product using AI to forecast hypoglycaemia risk 30 minutes ahead and glucose levels two hours ahead, again assisting rather than acting on its own.
Who it is priced against
Closelooknet groups Roche with Eli Lilly, Natera and AstraZeneca inside the AI Users Research, Design & Development section; the market also sets it against Novartis, the other large Swiss pharmaceutical group.
Why Closelooknet tracks it
Roche holds no Rubin or Halo seat; it sits in the AI Users index as a Research, Design & Development constituent. Closelooknet's score for Roche is still developing across three modules, with quality the strongest and valuation the weakest.
What the diary watches
The diary watches whether the gRED Research Agent, which Roche said in May 2025 would automate more than 43,000 hours of biomarker-validation work, moves toward the planned network of specialised sub-agents.

Roche Holding AG (ROP.SW) trades on the SW exchange in Switzerland, classified under Healthcare.

The Closelooknet company score reads 56/100 composite (momentum 83, quality 84, valuation 51) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelooknet’s own readings, 2026-10-25. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Dividends and capital return trailing yield 2.44%, annual · buybacks 987 m CHF in FY2025

Dividends and capital return

What ROP.SW pays out and buys back — distributions read from the price series, money terms from the filings.

  • Trailing 12 months 9.80 CHF per share · a 2.44% yield on the 2026-11-10 close 1 distribution, paid once a year 2026-11-10
  • Change on the year +1.0% against the prior twelve months prior twelve months 9.70 CHF per share
  • Last distribution 9.80 CHF per share as the price series records it, within days of the ex-date 2026-03-12
  • By calendar year 2025: 9.70 CHF (partial) · 2026: 9.80 CHF to date first distribution recorded in the three-year window: 2025-03-27
  • Dividends paid, FY2025 8.39 bn CHF 64% of earnings
  • Buybacks, FY2025 987 m CHF 0.3% of today's market value
  • Share count +0.1% in FY2025 857 m CHF of stock-based compensation in the year
  • Capital returned 9.37 bn CHF · 67% of free cash flow dividends and buybacks together, against the year’s free cash flow

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

FAQ · from the current data · as of 2026-11-11

Quick answers

What is Roche Holding AG (ROP.SW)?

Roche Holding AG trades as ROP.SW on the SW exchange (Switzerland) and is classified under Healthcare in the Closelooknet research universe, as of the registry build of 2026-11-11.

Is ROP.SW in a Closelooknet index?

Not currently — Roche Holding AG is tracked in the Closelooknet research universe but is not a constituent of a Closelooknet functional index as of 2026-11-11.

What is Roche Holding AG's Closelooknet composite score?

56 out of 100, with momentum 83, quality 84 and valuation 51 sub-scores, as of 2026-11-11. Scores are Closelooknet's own research readings, not ratings or investment advice.

Where does ROP.SW trade against its moving averages?

Roche Holding AG trades 8.6% above its 50-day and 16.8% above its 200-day moving average (2.5% above its 20-day). As of 2026-11-10 — a technical state from the nightly Closelooknet bake, not advice. The Technical tab carries the full row.

How is ROP.SW doing against its Closelooknet index?

Over the past month Roche Holding AG is +11.6% against +5.5% for the AI Users — 6.1 points ahead of its index, as of 2026-11-10. Its Research, Design & Development sleeve is +8.0% over the same month. The “Versus its index” table on this page carries the day, the week and the month for the name, its sleeve and the index.

How does Roche Holding AG compare with its peers?

Against its peer group (AI Users · Research, Design & Development), Roche Holding AG (ROP.SW) sits 1.0% below its 52-week high, 8.6% above its 50-day average; Eli Lilly and Company (LLY) is 2.8% below, AstraZeneca PLC (AZN.L) is 10.2% below, Natera Inc (NTRA) is 26.8% below, as of 2026-11-10. Put any of them next to ROP.SW in the chart grid (2×1 or 2×2) and the page lays the companies side by side: performance, trend, valuation, margins and our money-flow reading.

What does Roche Holding AG do?

Roche Holding AG is a Swiss healthcare group split between pharmaceuticals and diagnostics, headquartered in Basel. Its medicines cover areas such as oncology, immunology, neurology, ophthalmology and infectious disease, while its diagnostics arm supplies tests and instruments used to detect conditions including cancer, diabetes and hepatitis. The company was founded in 1896 and sells across North America, Europe, Latin America, Asia, Africa and Oceania. Closelooknet groups Roche with Eli Lilly, Natera and AstraZeneca inside the AI Users Research, Design & Development section; the market also sets it against Novartis, the other large Swiss pharmaceutical group. (Company snapshot of 2026-10-25.)

Where does Roche Holding AG sit in the AI build-out?

Roche sits in the AI Users index (our index of companies deploying AI at scale to strengthen their existing businesses), in the Research, Design & Development section. It disclosed in February 2025 that AI-assisted antibody lead optimisation designed and tested more than 1,800 variants, producing binding improvements of three to 100 times, with scientists assessing the results rather than the system deciding on its own. It also disclosed in July 2024 a diagnostics product using AI to forecast hypoglycaemia risk 30 minutes ahead and glucose levels two hours ahead, again assisting rather than acting on its own. Roche holds no Rubin or Halo seat; it sits in the AI Users index as a Research, Design & Development constituent. Closelooknet's score for Roche is still developing across three modules, with quality the strongest and valuation the weakest. (Company snapshot of 2026-10-25.)

Does Roche Holding AG pay a dividend?

Roche Holding AG has paid 9.80 CHF per share over the last twelve months, paid once a year, a trailing yield of 2.44% on the 2026-11-10 close; the last distribution recorded in the price series was 9.80 CHF on 2026-03-12. In fiscal 2025 the company paid 8.39 bn CHF in dividends and bought back 987 m CHF of its own shares, 67% of that year’s free cash flow. The share count rose 0.1% over the fiscal year. As of 2026-11-10; the "Dividends and capital return" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for ROP.SW, performance metrics, index-membership context and the Closelooknet structure read — an investment research diary view, not investment advice.

How to use this chart

Toolbar

  • Range — 1M to MAX on daily closes. 1D/5D switch a US stock cell to 5-minute intraday bars; index and foreign cells fall back to 1M daily with a note.
  • Grid — 1×1 up to 2×2. Cells are synchronized: pan or zoom one and the others follow the same dates; the crosshair tracks across all of them. 4 INDICES loads Rubin · HALO · AEI · AW40 side by side.
  • Type / Scale — OHLC, line or area; linear or log price axis.

Picking a series

  • Tap the box in a cell's header to browse every Closelooknet series — headline indices, sub-indices, sectors, layers of all six families — plus the constituents.
  • Or type any ticker (NVDA, 7203.T, ASML.AS …) and press Enter — it charts in the cell straight from our data lake.

Studies

  • Overlays / Oscillators rows toggle the standard set (SMA, Bollinger, RSI, MACD …) per cell.
  • Levels (stock cells) draws the structure engine's support lines — regression bands, pivot cluster, SMA-200, the active fib zone.

Drawing

  • Tap a tool (Trend, Ray, H-Line, Fib, Channel, Rect, Note), then tap the chart once per point — the shape follows your finger or cursor between taps. The chart stops panning while a tool is armed; tap the tool again to release.
  • Drawings save per symbol in this browser and travel between the terminal and the asset page.
  • Delete key removes the selected drawing · Escape cancels a half-placed one · Clear wipes the symbol.

Wave counts

  • Wave places an Elliott count: tap the origin, then each wave end. Press Enter to stop early (inside wave 3 is fine) — dotted ghost targets sketch the remaining waves at guideline ratios.
  • On stocks the scanner's machine count appears automatically in grey — it is fully editable: drag any point, double-tap a label to remove it, Delete to dismiss it for good, Adopt to bring the machine's proposal back.
  • The sequence picker switches 1-5 / A-B-C / A-E / W-X-Y-Z; 1 2 3 cycles the degree; Subdiv starts a one-degree-smaller child count inside a wave.

Sharing

  • Card exports the cell as a branded PNG — chart, drawings and levels exactly as shown.

Related in the Closelooknet universe